PO.CL05.03 · 临床研究

单例患者中四种免疫治疗毒性的独特表现

The unique presentation of four immunotherapy toxicities in a single patient

编号 3803 展板 18 时间 4/20 02:00–05:00 区域 Section 43 主讲 Orianna Guarisma-Lugo, AA
分会场 Combination Immunotherapies
该海报暂无可下载的资料 AACR 官方页面

作者与单位 Authors & Affiliations

Orianna Guarisma-Lugo1, Roderick Brice1, Samuel Ramirez1, Winston W. Tan2

1Hematology-Oncology, Mayo Clinic Florida, Jacksonville, FL,2Assistant Professor, Dept. of Hem./Onc., Mayo Clinic Florida, Jacksonville, FL

摘要 Abstract

中文摘要
免疫治疗的医学进展已治愈了一些既往无法治愈的转移性肾癌患者。我们报告一例74岁男性转移性肾癌患者,仅接受了一剂伊匹木单抗(ipilimumab)联合纳武利尤单抗(nivolumab)治疗。在对治疗的反应中,他出现了自身免疫性肝炎、重症肌无力、肌炎和心肌炎。尽管这些严重的副作用被认为很少发生,但它们可迅速危及生命甚至致命。这些免疫相关不良事件(irAEs)可能进一步发展为继发的危及生命的症状,如进展性重症肌无力导致的呼吸衰竭;心肌炎的心脏毒性可能引起心源性休克、心脏骤停和严重心力衰竭;以及自身免疫性肝炎继而导致的肝衰竭。此外,医生能够早期发现免疫治疗毒性对于及时干预、避免患者出现致命状况极为重要。对于接受免疫治疗的患者,沟通、协作和多学科诊疗至关重要。其健康状况或症状的任何细微或突然变化都应促使进一步检查。我们的目的是通过强调该患者病例来提高对毒性的认识,以在未来数年内显著降低致死率并提高该治疗的成功率。
查看英文原文 English abstract
Medical advancements with immunotherapy have cured some patients with previously incurable metastatic renal cancer. We present the case of a 74-year-old male metastatic renal cancer patient who received only one dose of the combination of ipilimumab with nivolumab. In response to his treatment, he developed autoimmune hepatitis, myasthenia, myositis, and myocarditis. Although these serious side effects are considered to rarely occur, they can quickly become life-threatening and even fatal. These immune-related adverse events (irAEs) may further develop into secondary life-threatening symptoms such as respiratory failure due to advanced myasthenia; cardiotoxicity of myocarditis with possible cardiogenic shock, cardiac arrest, and severe heart failure; and liver failure consequently from autoimmune hepatitis. Furthermore, the ability for physicians to detect immunotherapy toxicity early is extremely important in intervening in a timely manner to avoid lethal conditions for the patient. With patients receiving immunotherapy, communication, collaboration, and multidisciplinary care are essential. Any subtle or sudden changes in their health status or symptoms should prompt further investigation. It is our purpose to highlight this patient to raise awareness of toxicity to significantly reduce the fatality rates and increase the therapy's success rate in the years to come.
利益披露 Disclosure
O. Guarisma-Lugo, None.. R. Brice, None.. S. Ramirez, None.

← 返回 AACR 2026 检索